Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 1:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 16,848 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Respiratory Tract Disease Clear all
Completed Phase 1 Interventional

Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

NCT04040231
View directory record Official record
Conditions
Mesothelioma, Pleural Mesothelioma, Wilms Tumor
Interventions
Galinpepimut-S, Nivolumab, Sargramostim
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 14, 2026, 1:50 AM EDT
Completed No phase listed Observational

Bacterial Pulmonary Infection in PICU

NCT00271531
View directory record Official record
Conditions
Bacterial Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Months to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
4
States / cities
Louisville, Kentucky • St Louis, Missouri • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2011 · Synced Oct 14, 2026, 1:50 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Pain Management Following Sinus Surgery

NCT03822962
View directory record Official record
Conditions
Nasal Sinus; Inflammation, Opioid Abuse, Pain, Postoperative
Interventions
Ibuprofen 600Mg Tablet, Standard Regimen | Tylenol
Drug · Other
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Omaha, Nebraska • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 14, 2026, 1:50 AM EDT
Completed Phase 2 Interventional Results available

Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer

NCT00284154
View directory record Official record
Conditions
Carcinoma, Small Cell, Lung Cancer
Interventions
Vinflunine
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Fort Myers, Florida • Cincinnati, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Oct 14, 2026, 1:50 AM EDT
Terminated Not applicable Interventional Results available

Continuous Positive Airway Pressure and Cardiometabolic Risk

NCT01403194
View directory record Official record
Conditions
Sleep Disordered Breathing
Interventions
CPAP/BiPAP
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
8 Years to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Oct 14, 2026, 1:50 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)

NCT00883129
View directory record Official record
Conditions
Scleroderma, Interstitial Lung Disease
Interventions
Mycophenolate mofetil, Cyclophosphamide, Placebo
Drug
Lead sponsor
Michael Roth
Other
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 14, 2026, 1:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Trial to Evaluate the Use of Pomegranate Concentrate (POMx) for the Prevention of Experimental Rhinovirus Infection

NCT00655031
View directory record Official record
Conditions
Common Cold
Interventions
Pomegranate Concentrate (POMx), Placebo
Dietary Supplement
Lead sponsor
POM Wonderful LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
3
States / cities
Huntsville, Alabama • Melbourne, Florida • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2008 · Synced Oct 14, 2026, 1:50 AM EDT
Completed Phase 4 Interventional Results available

Outcomes of Once-Daily ICS/LABA/LAMA + PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations

NCT05292053
View directory record Official record
Conditions
Copd
Interventions
TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg/Actuation Powder for Inhalation
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 14, 2026, 1:50 AM EDT
Active, not recruiting Phase 2 Interventional

Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer

NCT04397003
View directory record Official record
Conditions
Extensive-stage Small Cell Lung Cancer
Interventions
Neoantigen DNA vaccine, Durvalumab, TDS-IM v2.0 Device, Peripheral blood draws
Biological · Drug · Device + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 14, 2026, 1:50 AM EDT
Completed Phase 2 Interventional

Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC

NCT00156286
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Gleevec
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 16, 2010 · Synced Oct 14, 2026, 1:50 AM EDT
Completed No phase listed Observational

A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.

NCT05230186
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
Tumor Biopsy
Procedure
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Los Angeles, California • New Orleans, Louisiana • Morristown, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 14, 2026, 1:50 AM EDT
Completed Phase 2 Interventional Results available

Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment

NCT00807573
View directory record Official record
Conditions
Lung Cancer
Interventions
Paclitaxel, Pemetrexed, Bevacizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Oct 14, 2026, 1:50 AM EDT
Terminated Early Phase 1 Interventional

Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients

NCT04213794
View directory record Official record
Conditions
Malignant Abdominal Neoplasm, Malignant Pelvic Neoplasm, Recurrent Colon Carcinoma, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Gastric Carcinoma, Recurrent Liposarcoma, Recurrent Malignant Mesothelioma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Rectal Carcinoma, Recurrent Rhabdomyosarcoma, Recurrent Sarcoma, Refractory Colon Carcinoma, Refractory Desmoplastic Small Round Cell Tumor, Refractory Fallopian Tube Carcinoma, Refractory Gastric Carcinoma, Refractory Liposarcoma, Refractory Malignant Mesothelioma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma, Refractory Rectal Carcinoma, Refractory Rhabdomyosarcoma, Refractory Sarcoma, Resectable Liposarcoma, Resectable Malignant Mesothelioma, Resectable Sarcoma
Interventions
Cisplatin, Cytoreductive Surgery, Doxorubicin, Hyperthermic Intraperitoneal Chemotherapy, Sodium Thiosulfate, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Biospecimen Collection
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
1 Year to 25 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 14, 2026, 1:50 AM EDT
Completed Phase 1 Interventional

6R-BH4 Pulmonary Arterial Hypertension Study

NCT00435331
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
sapropterin dihydrochloride (6R-BH4)
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 14, 2026, 1:50 AM EDT
Terminated Phase 3 Interventional Results available

A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension

NCT03657095
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Esuberaprost, Placebo
Drug
Lead sponsor
Lung Biotechnology PBC
Industry
Eligibility
18 Years to 85 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2020 · Synced Oct 14, 2026, 1:50 AM EDT
Not listed No phase listed Observational

COVID-19 & Psychiatry: A Retrospective Chart Review

NCT05244096
View directory record Official record
Conditions
COVID-19
Interventions
No intervention
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
65,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 14, 2026, 1:50 AM EDT
Completed Phase 4 Interventional Results available

Comparing Fluticasone-salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep

NCT00731770
View directory record Official record
Conditions
COPD
Interventions
Advair 250, Placebo- matched, Placebo, Advair 250 - matched
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
45 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Oct 14, 2026, 1:50 AM EDT
Completed Phase 2 Interventional Results available

Chronic Evaluation of Respicardia Therapy

NCT01124370
View directory record Official record
Conditions
Sleep Disordered Breathing, Cheyne Stokes Respiration, Periodic Breathing, Sleep Apnea, Central Sleep Apnea
Interventions
remedē (TM) system
Device
Lead sponsor
Respicardia, Inc.
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
5
States / cities
Lincoln, Nebraska • Columbus, Ohio • Lancaster, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 14, 2026, 1:50 AM EDT
Completed Phase 2 Interventional Results available

Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)

NCT02097641
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells, Plasma-Lyte A
Biological
Lead sponsor
Michael A. Matthay
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
San Francisco, California • Stanford, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 14, 2026, 1:50 AM EDT
Recruiting Phase 2 Interventional

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT06967805
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
MTX-463, Placebo
Biological · Other
Lead sponsor
Mediar Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 14, 2026, 1:50 AM EDT
Completed Not applicable Interventional

Feasibility of a Physical Therapy Intervention on Older Adults With Hyperkyphosis or Forward Head Posture

NCT04114331
View directory record Official record
Conditions
Pneumonia, COPD, Hyperkyphosis, Postural, Thoracic Kyphosis
Interventions
Manual therapy and exercise
Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 14, 2026, 1:50 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults

NCT04816669
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
BNT162b2
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 55 Years
Enrollment
629 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
21
States / cities
Anaheim, California • Walnut Creek, California • Hialeah, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Oct 14, 2026, 1:50 AM EDT
Terminated Phase 2 Interventional Results available

Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer

NCT04162873
View directory record Official record
Conditions
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Nasal Cavity and Paranasal Sinus Carcinoma, Oral Cavity Carcinoma, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Hypopharyngeal Carcinoma, Recurrent Laryngeal Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Carcinoma, Recurrent Oral Cavity Carcinoma, Recurrent Oropharyngeal Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVC Hypopharyngeal Carcinoma AJCC v8, Stage IVC Laryngeal Cancer AJCC v8, Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Celecoxib, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 14, 2026, 1:50 AM EDT
Terminated Not applicable Interventional Results available

Respiratory Muscle Strength in Patients With NMD

NCT01555905
View directory record Official record
Conditions
Neuromuscular Disease
Interventions
Threshold PEP or IMT device Phillips-Respironics
Device
Lead sponsor
University of Florida
Other
Eligibility
6 Months to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 14, 2026, 1:50 AM EDT